US: Robins Kaplan LLP Appointed Co-Lead counsel in antitrust collusion suit

Robins Kaplan filed the first complaint in the country in November 2016 alleging that defendants Baxter International, Baxter Healthcare, and Hospira—which together control approximately 90 percent of the market—orchestrated an artificial rise in prices under the pretext of a supply shortage.

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Add as Preferred Source

“The complaint alleges that the defendants created a public health crisis—one that was avoidable and that unnecessarily drove up the cost of healthcare for hospitals and vulnerable patients,” said Hollis Salzman, co-chair of Robins Kaplan’s Antitrust and Trade Regulation group. “We look forward to pursuing this action, obtaining redress for hospitals and others that have paid a higher price resulting from the defendants’ alleged collusion.”

According to the allegations in the complaint, beginning in 2013 the defendants undertook extensive efforts to create a supply shortage that would justify price increases, including allocating the volume of product that each would place on the market. In addition, as the purported shortage extended over time, it became the subject of Congressional scrutiny. Approximately one year ago, a bipartisan group of U.S. senators urged the Federal Trade Commission to investigate possible collusion among saline suppliers, which it noted “are reported to have increased their prices by 200-300 percent.” The letter continued: “This equates to increased annual costs to individual hospitals in the range of hundreds of thousands to millions of dollars.”

Full Content: Business Wire

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.